Download PDF
Zeitschrift für Komplementärmedizin 2016; 08(6): 21-27
DOI: 10.1055/s-0042-120834
Praxis
Phytotherapie
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Phytotherapie bei Erkrankungen der Prostata

Karen Nieber
Subject Editor:
Further Information

Publication History

Publication Date:
23 December 2016 (online)

    Permissions and Reprints

Summary

In der Urologie haben Phytopharmaka eine lange Tradition. Extrakte aus Sägepalmfrüchten, Kürbissamen oder Roggenpollen wurden in klinischen Studien bei Patienten mit benignem Prostatasyndrom intensiv untersucht. Die Studienlage ist sehr heterogen und lässt noch keine abschließende Beurteilung der Wirksamkeit zu, auch wenn die bisherigen Resultate vielversprechend sind. Für die Anwendung bei der abakteriellen Prostatitis oder beim Prostatakarzinom gibt es erste Hinweise zur Wirksamkeit von pflanzlichen Mitteln.

Keywords

Prostatahyperplasie - Prostatitis - Prostatakarzinom - Phytotherapie
 

  • Literatur

  • 1 Hautmann R. Urologie. 4. Aufl. Heidelberg: Springer; 2010
    CrossrefGoogle Scholar
  • 2 Coyne KS, Sexton CC, Thompson CL et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (Epi-LUTS) study. BJU Int 2009; 104: 352-360
    CrossrefGoogle Scholar
  • 3 Wehrberger C, Dreikorn K, Schmitz-Dräger BJ et al. Phytotherapie bei benignem Prostatasyndrom und Prostatakarzinom. Urologe 2012; 51: 1674-1682
    CrossrefGoogle Scholar
  • 4 Berges R, Dreikorn K, Höfner K et al. Diagnostik und Differenzialdiagnostik des benignen Prostatasyndroms (BPS): Leitlinien der Deutschen Urologen. Urologe A 2009; 48: 1356-1360 1362–1354
    CrossrefGoogle Scholar
  • 5 Leitlinie zur Therapie des benignen Prostatasyndroms der Qualität S2e 2014, AWMF-Reg. Nr: 043–035, 2014
  • 6 Nickel JC, Shoskes D, Roehrborn C et al. Nutraceuticals in prostate disease: the urologist’s role. Rev Urol 2008; 10: 192-206
    Google Scholar
  • 7 Hardtke K et al. Hrsg. Kommentar zum Europäischen Arzneibuch Ph. Eur. 5.0, Sägepalmenfrüchte. Loseblattsammlung, 23. Lieferung 2006. Stuttgart: Wissenschaftliche Verlagsgesellschaft;
    Google Scholar
  • 8 Wilt T, Ishani A, Mac DR et al. Pygeum africanum for benign prostatic hyperplasia. 2002; Cochrane Database Syst Rev CD001044
    Google Scholar
  • 9 MacDonald R, Tacklind JW, Rutks I et al. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int 2012; 109 (12) 1756-1761
    CrossrefGoogle Scholar
  • 10 Tacklind J, Macdonald R, Rutks I et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2012; 12: CD001423
    Google Scholar
  • 11 Görne RC. Systematisches Review zur Therapie von Symptomen der unteren Harnwege (LUTS) mit und ohne benigne Prostatahyperplasie (BPH) mit alkoholischen Extrakten von Sägepalmenfrüchten. Z Phytother 2014; 35 (03) 111-118
    Article in Thieme ConnectGoogle Scholar
  • 12 Lopatkin N, Sivkov A, Walther C et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms – a placebo-controlled, double-blind, multicenter trial. World J Urol 2005; 23 (2) 139-146
    CrossrefGoogle Scholar
  • 13 Sökeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU Int 2000; 86 (4) 439-442
    CrossrefGoogle Scholar
  • 14 Engelmann U, Walther C, Bondarenko B et al. Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittelforschung 2006; 56 (3) 222-229
    Google Scholar
  • 15 Strobl M, Patz B, Bracher F. Kürbissamen bei Störungen der Blasenfunktion. DAZ 2004; 144: 4010-4014
    Google Scholar
  • 16 Bracher F, Plössl F. Identification and determination of phytosterols in pharmaceutical preparations. Annu Meet DPhG (Deutsche Pharmazeutische Gesellschaft) Jena: 2009
    Google Scholar
  • 17 Committee on Herbal Medicinal Products (HMPC) Assessment report on Cucurbita pepo L., semen. EMA / HMPC/136022/2010, Nov 20, 2012 first published March 25, 2013
  • 18 Abdel-Rahman MK. Effect of pumpkin seed (Cucurbita pepo L.) diets on benign prostatic hyperplasia (BPH): chemical and morphometric evaluation in rats. World J Chem 2006; 1: 33-40
    Google Scholar
  • 19 Gossell-Williams M, Davis A, O‘Connor N. Inhibition of testosterone-induced hyperplasia of the prostate of Sprague-Dawley rats by pumpkin seed oil. J Med Food 2006; 9: 284-286
    CrossrefGoogle Scholar
  • 20 Schmidlin C, Kreuter M. Cucurbita pepo. Möglicher Einfluss auf hormonelle Ungleichgewichte bei Inkontinenz. Z Phytotherapie 2003; 3: 16-18
    Google Scholar
  • 21 Vahlensieck W, Theurer C, Pfitzer E et al. Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urol Int 2015; 94: 286-295
    CrossrefGoogle Scholar
  • 22 Schneider T, Ruebben H. Stinging nettle root extract (Bazoton-uno) in long term treatment of benign prostatic syndrome (BPS). Results of a randomized, double-blind, placebo controlled multicenter study after 12 months. Urologe A 2004; 43: 302-306
    CrossrefGoogle Scholar
  • 23 Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother 2005; 5: 1-11
    Google Scholar
  • 24 Wilt R, Mac Donald A, Ishani I et al. Cernilton for benign prostatic hyperplasia. In: Cochrane database of systematic reviews (Online). 2000; 2: CD001042
    Google Scholar
  • 25 Dreikorn K, Schönhöfer PS. Stellenwert von Phytotherapeutika bei der Behandlung der benignen Prostatahyperplasie (BPH). Urologe A 1995; 34: 119-129
    Google Scholar
  • 26 Engelmann U, Boos G, Kres H. Therapie der benignen Prostatahyperplasie mit Bazoton Liquidum. Urologe B 1996; 36: 287-291
    CrossrefGoogle Scholar
  • 27 Wagenlehner FME, Schneider H, Ludwig M et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis – chronic pelvic pain syndrome: a multicentre randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol 2009; 56: 544-551
    CrossrefGoogle Scholar
  • 28 Shoskes DA, Zeitlin SI, Shahed A et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999; 54: 960-963
    CrossrefGoogle Scholar
  • 29 Melzer J, Schrader E, Brattström A et al. Fixed herbal drug combination with and without butterbur (Ze 185) for the treatment of patients with somatoform disorders: randomized, placebo-controlled pharmacoclinical trial. Phytother Res 2009; 23: 1303-1308
    CrossrefPubMedGoogle Scholar
  • 30 Bettuzzi S, Brausi M, Rizzi F et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66: 1234-1240
    CrossrefGoogle Scholar
  • 31 Paller CJ, Wozniak PJ, Gillespie BK et al. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis 2013; 16: 50-55
    CrossrefGoogle Scholar
  • 32 Thomas R, Williams M, Sharma H et al. A double-blind, placebo-controlled randomized trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer – the UK NCRN Pomi-T study. Prostate Cancer Prostatic Dis 2014; 17 (2) 180-186
    CrossrefGoogle Scholar
  • 33 Schaeffer AJ. Etiology and management of chronic pelvic pain syndrome in men. Urology 2004; 63: 75-84
    CrossrefGoogle Scholar
  • 34 www.consort-statement.org (Zugriff: 21.11.2016)
  • 35 van Die MD, Bone KM, Emery J et al. Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials. BJU Int. 2016; Apr 117 (Suppl 4) 17-34
    CrossrefGoogle Scholar